Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harrow Health Inc (HROW) Financials: Revenue, Profit and Cash Flow
Harrow Health reported revenue of $272.30M for the fiscal year ended Dec 31, 2025, up 36.4% from the year before. That year, net income was -$5.14M with a net margin of -1.9%, operating cash flow was $43.86M and free cash flow was $42.98M. The quarter ended Sep 30, 2026 had revenue of $99.30M and net income of $9.76M.
Revenue and Margins
The operating margin was 11.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $19.94M, a compound annual rate of 33.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $272.30M | +36.4% | 75.1% | 11.2% | -1.9% |
| Dec 2024 | $199.61M | +53.3% | 75.3% | 4.4% | -8.8% |
| Dec 2023 | $130.19M | +47.0% | 69.6% | 0.3% | -18.7% |
| Dec 2022 | $88.59M | +22.2% | 71.3% | 2.2% | -15.9% |
| Dec 2021 | $72.48M | +48.3% | 74.9% | 2.2% | -24.8% |
| Dec 2020 | $48.87M | -4.5% | 70.4% | 0.8% | -7.0% |
| Dec 2019 | $51.16M | +23.7% | 67.3% | -9.4% | -0.2% |
| Dec 2018 | $41.37M | +54.5% | 60.1% | -12.6% | 35.3% |
| Dec 2017 | $26.77M | +34.3% | 49.6% | -45.4% | -44.8% |
| Dec 2016 | $19.94M | N/A | 50.7% | -79.6% | -95.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 856.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272.30M | $199.61M | $130.19M | $88.59M | $72.48M | $48.87M | $51.16M | $41.37M | $26.77M | $19.94M |
| Cost of revenue | $67.93M | $49.24M | $39.64M | $25.38M | $18.21M | $14.46M | $16.75M | $16.52M | $13.51M | $9.83M |
| Gross profit | $204.37M | $150.37M | $90.55M | $63.21M | $54.26M | $34.41M | $34.42M | $24.85M | $13.27M | $10.11M |
| Research and development | $20.94M | $12.23M | $6.65M | $3.05M | $11.08M | $2.41M | $2.08M | $825.00K | $413.00K | $739.00K |
| Operating income | $30.52M | $8.82M | $431.00K | $1.92M | $1.61M | $385.00K | -$4.79M | -$5.22M | -$12.16M | -$15.88M |
| Net income | -$5.14M | -$17.48M | -$24.41M | -$14.09M | -$18.01M | -$3.42M | -$125.00K | $14.63M | -$11.98M | -$19.09M |
| EBITDA | $53.52M | $26.48M | $15.70M | N/A | N/A | N/A | -$990.00K | -$3.05M | -$10.66M | -$12.08M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.30M | $70.66M | $44.20M | $89.09M | $71.64M | $63.74M | $47.83M | $66.83M | $49.26M | $48.94M | $34.59M | $36.35M |
| Gross profit | $74.90M | $50.36M | $27.05M | $70.62M | $53.93M | $47.51M | $32.31M | $52.70M | $37.24M | $36.40M | $24.03M | $25.05M |
| Operating income | $11.47M | -$11.01M | -$22.08M | $15.59M | $14.75M | $11.41M | -$11.23M | $12.90M | $1.32M | $1.53M | -$6.93M | -$4.88M |
| Net income | $9.76M | -$17.27M | -$27.60M | $6.63M | $1.02M | $5.00M | -$17.78M | $6.78M | -$4.22M | -$6.47M | -$13.56M | -$9.15M |
Balance Sheet
As of Dec 2025, total debt of $244.07M exceeded cash and equivalents by $171.14M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $399.48M | $388.97M | $312.16M | $157.38M | $98.33M | $57.47M | $59.09M | $49.45M | $23.92M | $27.25M |
| Current assets | $211.75M | $189.65M | $139.48M | $118.26M | $60.66M | $40.98M | $36.05M | $32.84M | $8.81M | $14.75M |
| Cash and equivalents | $72.93M | $47.25M | $74.08M | $96.27M | $42.17M | $4.10M | $4.75M | $6.64M | $4.02M | $8.85M |
| Total liabilities | $347.39M | $319.67M | $241.75M | $130.14M | $87.40M | $30.65M | $31.67M | $24.70M | $21.30M | $20.82M |
| Short-term debt | $887.00K | $497.00K | $806.00K | $723.00K | $280.00K | $3.90M | $1.77M | $2.53M | $598.00K | $4.43M |
| Long-term debt | $243.18M | $219.54M | $185.88M | $104.17M | $71.65M | $12.38M | $12.22M | $12.00M | $14.01M | $7.94M |
| Shareholder equity | $52.45M | $69.65M | $70.77M | $27.59M | $11.29M | $27.18M | $27.71M | $24.75M | $2.62M | $6.43M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $443.02M | $416.82M | $419.54M | $399.48M | $363.07M | $345.03M | $364.16M | $388.97M | $351.54M | $306.63M | $295.54M | $311.75M |
| Total liabilities | $414.19M | $401.97M | $391.19M | $347.39M | $316.41M | $295.73M | $308.07M | $319.67M | $293.92M | $248.45M | $235.33M | $241.75M |
| Cash and equivalents | $75.34M | $83.89M | $94.64M | $72.93M | $74.29M | $52.96M | $66.73M | $47.25M | $72.60M | $70.97M | $68.54M | $74.08M |
| Shareholder equity | $29.19M | $15.20M | $28.71M | $52.45M | $47.02M | $49.65M | $56.45M | $69.65M | $57.98M | $58.53M | $60.56M | $70.36M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $43.86M | -$22.20M | $3.84M | $1.71M | $5.08M | -$1.10M | $950.00K | $687.00K | -$8.80M | -$11.21M |
| Capital expenditures | $887.00K | $1.59M | $1.46M | $2.60M | $1.79M | $862.00K | $1.47M | $1.77M | $772.00K | $6.89M |
| Free cash flow | $42.98M | -$23.80M | $2.38M | -$892.00K | $3.30M | -$1.96M | -$518.00K | -$1.08M | -$9.57M | -$18.10M |
| Dividends paid | N/A | N/A | N/A | $876.00K | $127.00K | $0 | $127.00K | $127.00K | N/A | $4.32M |
| Investing cash flow | -$5.46M | -$33.16M | -$152.55M | -$1.74M | -$18.69M | -$981.00K | -$1.83M | -$2.20M | -$961.00K | -$7.29M |
| Financing cash flow | -$12.72M | $28.53M | $126.53M | $54.14M | $51.47M | $1.43M | -$1.01M | $4.13M | $4.93M | $24.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.62M | -$9.76M | -$8.99M | $8.41M | $16.59M | -$803.00K | $19.67M | -$17.78M | $2.95M | -$2.75M | -$4.63M | $8.70M |
| Capital expenditures | $375.00K | $491.00K | $194.00K | $341.00K | $210.00K | $166.00K | $170.00K | $555.00K | $604.00K | $344.00K | $92.00K | $194.00K |
| Free cash flow | -$8.99M | -$10.25M | -$9.19M | $8.07M | $16.38M | -$969.00K | $19.50M | -$18.33M | $2.35M | -$3.09M | -$4.72M | $8.50M |
Frequently Asked Questions About HROW
What is Harrow Health's annual revenue?
Harrow Health reported revenue of $272.30M for the fiscal year ended Dec 31, 2025.
How fast is Harrow Health's revenue growing?
Revenue was up 36.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 45.4%.
Is Harrow Health profitable?
No. Harrow Health reported net income of -$5.14M for the fiscal year ended Dec 31, 2025, with a net margin of -1.9%.
How much free cash flow does HROW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $43.86M minus capital expenditures of $887.00K produced free cash flow of $42.98M.
How much debt does Harrow Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $243.18M, short-term debt of $887.00K and cash and equivalents of $72.93M.
HROW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors